Syn-One Test
Commercial- Indications
- Parkinson's disease, Multiple system atrophy, Dementia with Lewy bodies, Pure autonomic failure
Company intelligence / Profile preview
CND Life Sciences has commercialized the Syn-One Test®, a CLIA-certified, CAP-accredited diagnostic that uses skin biopsies to detect phosphorylated alpha-synuclein with >95% sensitivity and specificity. The test is used by thousands of clinicians and has aided diagnosis in over 35,000 patients. Published data in JAMA confirm its high accuracy. The company is expanding its technology platform to other neurodegenerative disease biomarkers and collaborates with biopharma on clinical trials.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CND Life Sciences.